Page 244 - Haematologica Vol. 110 - January 2025

LETTER TO THE EDITOR
treatment with TBI plus etoposide or chemoconditioning. Persistence of MRD after induction with chemotherapy and prior to alloHSCT has been demonstrated to be predictive of recurrence of B-ALL.7,10-13 A recently published post hoc analysis of data from a randomized phase III study6 demon-
A
strated that a higher proportion of patients with high-risk, first-relapse B-ALL with MRD had undetectable disease after receiving blinatumomab as their third consolidation course compared with patients treated with HC3. As pa- tients included in the current analysis were drawn from the
B
Figure 1. Post-transplant survival according to type of third consolidation and conditioning regimen. (A, B) Kaplan-Meier analysis for overall survival (A) and event-free survival (B) following allogeneic hematopoietic stem cell transplant in patients with high- risk, first-relapse B-cell acute lymphoblastic leukemia who received blinatumomab or chemotherapy as the third consolidation course and subsequently received either total body irradiation or chemotherapy as their conditioning regimen. The log-rank P value for all four subgroups was 0.0147 in (A) and 0.0568 in (B). Censor indicated by |. N: number of patients included in the anal- ysis; 95% CI: confidence interval; HC3: third consolidation course of chemotherapy; TBI: total body irradiation; NE: not estimable; chemo: chemotherapy.
Haematologica | 110 January 2025
236